Back to top

messenger-rna: Archive

Zacks Equity Research

MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback

Moderna's Q2 revenue tops estimates, but shares fall after its phase III norovirus vaccine study misses early success criteria.

MRNANegative Net Change MRKNegative Net Change ABUSPositive Net Change